As­traZeneca looks to widen its lead over SGLT2 ri­vals with an­oth­er round of land­mark da­ta

Com­pe­ti­tion be­tween SGLT2 in­hibitors in the chron­ic kid­ney dis­ease field just got more in­ter­est­ing. This week­end, As­traZeneca went to the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy’s 2020 meet­ing armed with full da­ta from a Phase III tri­al of its Farx­i­ga for a new in­di­ca­tion in CKD.

The drug is up against Eli Lil­ly and Boehringer In­gel­heim’s Jar­diance, which re­ceived FDA fast-track des­ig­na­tion in March for a CKD in­di­ca­tion, and John­son & John­son’s In­vokana, which won ap­proval last Sep­tem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER